- Pfizer Inc.
- GlaxoSmithKline PLC
- Elan Corp. PLC
- Vernalis Group PLC
- Menarini Industrie Farmaceutiche Riunite SRL
- Eisai Co. Ltd.
- Merck Serono SA
- Schering-Plough Corp.
- Abbott Laboratories Inc.
- Novartis AG
- Eli Lilly & Co.
- Forest Laboratories Inc.
- Warner Chilcott PLC
- Kos Pharmaceuticals Inc.
- Sunovion Pharmaceuticals Inc.
- Elan licenses rights to Vanguard's frovatriptan; terminated
- Glaxo, SmithKline merge
- Vanguard Medica to develop SmithKline's antimigraine drug
- Menarini markets Vanguard's frovatriptan in Europe
- Elan, UCB Pharma co-promote Frova in the US
- Eisai licenses rights to Zonegran from Elan
- British Biotech buys Vernalis for £47.3m
- British Biotech merges with RiboTargets
- Vanguard, F. Hoffman-La Roche develop obesity drugs
- British Biotech, Serono ally on inflammatory diseases
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.